Find Reports
Select Report Type
Reimbursement Review
Displaying 1101 - 1125 of 1426
Please scroll or swipe to the right to view the full content.
| Title | Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|---|
| CADTH Pharmaceutical Reviews U... | |||||||||
| CADTH Pharmaceutical Reviews U... | |||||||||
| fidaxomicin | Dificid | fidaxomicin | Clostridium difficile infection | N/A | Withdrawn | SF0847-000 | |||
| Colorectal cancer | Colorectal cancer | Withdrawn | PH0043-000 | ||||||
| nab-paclitaxel | N/A | nab-paclitaxel | Gastrointestinal cancer | Reimburse with clinical criteria and/or conditions | Complete | PX0360-000 | |||
| CADTH Pharmaceutical Reviews U... | |||||||||
| CADTH Pharmaceutical Reviews U... | |||||||||
| Biologics in Plaque Psoriasis | Complete | TS0001-000 | |||||||
| Pharmaceutical Reviews Update ... | |||||||||
| Acalabrutinib | Calquence | Acalabrutinib | Chronic Lymphocytic Leukemia (CLL) | Reimburse with clinical criteria and/or conditions | Complete | PC0211-000 | |||
| Nivolumab-Ipilimumab | Opdivo-Yervoy | Nivolumab-Ipilimumab | NSCLC | Reimburse with clinical criteria and/or conditions | Complete | PC0218-000 | |||
| ibrutinib | N/A | ibrutinib | Hematology | Received | PX0380-000 | ||||
| guanfacine hydrochloride exten... | N/A | guanfacine hydrochloride extended-release | Attention Deficit Hyperactivity Disorder (ADHD) | Pending | SX0755-000 | ||||
| Aripiprazole | N/A | Aripiprazole | Depression | Received | SX0756-000 | ||||
| vorasidenib | Voranigo | vorasidenib | Astrocytoma or oligodendroglioma; IDH1 or IDH2 mutation | Pending | PC0407-000 | ||||
| Pharmaceutical Reviews Update ... | |||||||||
| vanzacaftor, tezacaftor, deuti... | Alyftrek | vanzacaftor, tezacaftor, deutivacaftor | Cystic fibrosis, F508del or responsive CFTR mutation, 6 years and older | Pending | SR0896-000 | ||||
| inebilizumab | Uplizna | inebilizumab | Immunoglobulin G4-related disease | Pending | SR0889-000 | ||||
| upadacitinib | Rinvoq | upadacitinib | Giant cell arteritis | Pending | SR0877-000 | ||||
| trastuzumab deruxtecan | Enhertu | trastuzumab deruxtecan | HER2-low or HER2-ultralow breast cancer | Pending | PC0401-000 | ||||
| roflumilast | Zoryve | roflumilast | atopic dermatitis | Pending | SR0887-000 | ||||
| Nivolumab and ipilimumab | Opdivo and Yervoy | Nivolumab and ipilimumab | Unresectable or advanced hepatocellular carcinoma (HCC) | Pending | PC0420-000 | ||||
| teprotumumab | Tepezza | teprotumumab | Thyroid Eye Disease (TED), active | Active | SR0853-000 | ||||
| teprotumumab | TBC | teprotumumab | Thyroid Eye Disease (TED), chronic | Withdrawn | SR0853-001 | ||||
| isatuximab | Sarclisa | isatuximab | multiple myeloma not eligible for ASCT | Active | PC0378-000 |
Health Technology Review
Displaying 601 - 602 of 602
Horizon Scan
Displaying 101 - 110 of 110
Projects in Progress
Displaying 26 - 27 of 27
View All Reports
Displaying 1101 - 1125 of 2138
Please scroll or swipe to the right to view the full content.
Provisional Funding Algorithm
Displaying 76 - 81 of 81